Pemphigus Completed Phase 2 Trials for Infliximab (DB00065)

IndicationStatusPhase
DBCOND0001806 (Pemphigus)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00283712Use of Infliximab for the Treatment of Pemphigus VulgarisTreatment